134 related articles for article (PubMed ID: 9248260)
21. PET in lung cancer.
Coleman RE
J Nucl Med; 1999 May; 40(5):814-20. PubMed ID: 10319756
[TBL] [Abstract][Full Text] [Related]
22. Value of positron emission tomography for lung cancer staging.
Albes JM; Dohmen BM; Schott U; Schülen E; Wehrmann M; Ziemer G
Eur J Surg Oncol; 2002 Feb; 28(1):55-62. PubMed ID: 11869015
[TBL] [Abstract][Full Text] [Related]
23. Staging of non-small-cell lung cancer by whole-body fluorine-18 deoxyglucose positron emission tomography.
Bury T; Dowlati A; Paulus P; Hustinx R; Radermecker M; Rigo P
Eur J Nucl Med; 1996 Feb; 23(2):204-6. PubMed ID: 8925857
[TBL] [Abstract][Full Text] [Related]
24. Staging of non-small-cell lung cancer and application of FDG-PET. A cost modeling approach.
Verboom P; Herder GJ; Hoekstra OS; Smit EF; van den Bergh JH; van Velthoven PC; Grijseels EW
Int J Technol Assess Health Care; 2002; 18(3):576-85. PubMed ID: 12391950
[TBL] [Abstract][Full Text] [Related]
25. [Cost-effective PET scans in oncology].
Kálvin B; Fekésházy A; Lengyel Z; Szakáll S; Agoston P; Lengyel E; Székely J; Várady E; Galuska L; Trón L; Esik O
Orv Hetil; 2002 May; 143(21 Suppl 3):1255-61. PubMed ID: 12077909
[TBL] [Abstract][Full Text] [Related]
26. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation.
Wahl RL; Quint LE; Greenough RL; Meyer CR; White RI; Orringer MB
Radiology; 1994 May; 191(2):371-7. PubMed ID: 8153308
[TBL] [Abstract][Full Text] [Related]
27. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
[TBL] [Abstract][Full Text] [Related]
28. Lung cancer and positron emission tomography with fluorodeoxyglucose.
Marom EM; Erasmus JJ; Patz EF
Lung Cancer; 2000 Jun; 28(3):187-202. PubMed ID: 10812188
[TBL] [Abstract][Full Text] [Related]
29. Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling.
Steinert HC; Hauser M; Allemann F; Engel H; Berthold T; von Schulthess GK; Weder W
Radiology; 1997 Feb; 202(2):441-6. PubMed ID: 9015071
[TBL] [Abstract][Full Text] [Related]
30. [Diagnosis of early cancer with positron emission tomography].
Kubota K
Nihon Rinsho; 1996 May; 54(5):1263-7. PubMed ID: 8965348
[TBL] [Abstract][Full Text] [Related]
31. Mediastinal staging of non-small-cell lung cancer with positron emission tomography.
Chin R; Ward R; Keyes JW; Choplin RH; Reed JC; Wallenhaupt S; Hudspeth AS; Haponik EF
Am J Respir Crit Care Med; 1995 Dec; 152(6 Pt 1):2090-6. PubMed ID: 8520780
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic accuracy of 18F-2-deoxy-fluoro-D-glucose positron emission tomography for pN1 lymph nodes in patients with lung cancer.
Nakagawa M; Hara M; Sakurai K; Ozawa Y; Mizuno A; Tamaki T; Nishio M; Shibamoto Y
Acta Radiol; 2009 Jul; 50(6):638-44. PubMed ID: 19492198
[TBL] [Abstract][Full Text] [Related]
33. Whole-body 18F-2-deoxyglucose positron emission tomography in primary staging small cell lung cancer.
Shen YY; Shiau YC; Wang JJ; Ho ST; Kao CH
Anticancer Res; 2002; 22(2B):1257-64. PubMed ID: 12168935
[TBL] [Abstract][Full Text] [Related]
34. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
[TBL] [Abstract][Full Text] [Related]
35. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
36. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings.
Frank A; Lefkowitz D; Jaeger S; Gobar L; Sunderland J; Gupta N; Scott W; Mailliard J; Lynch H; Bishop J
Int J Radiat Oncol Biol Phys; 1995 Jul; 32(5):1495-512. PubMed ID: 7635795
[TBL] [Abstract][Full Text] [Related]
37. Thoracic FDG PET: state of the art.
Erasmus JJ; McAdams HP; Patz EF; Goodman PC; Coleman RE
Radiographics; 1998; 18(1):5-20. PubMed ID: 9460106
[TBL] [Abstract][Full Text] [Related]
38. [Impact of positron emission tomography on clinical management of potentially resectable non-small-cell lung cancer: a French prospective multicenter study].
Margery J; Milleron B; Vaylet F; Grahek D; Lebeau B; Mangiapan G; Bonardel G; de Labriolle-Vaylet C; Meignan M; Carette MF; Talbot JN; Housset B
Rev Pneumol Clin; 2010 Oct; 66(5):313-20. PubMed ID: 21087727
[TBL] [Abstract][Full Text] [Related]
39. [Meta-analysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose in lung tumors. Basis for discussion of the German Consensus Conference on PET in Oncology 2000].
Hellwig D; Ukena D; Paulsen F; Bamberg M; Kirsch CM;
Pneumologie; 2001 Aug; 55(8):367-77. PubMed ID: 11505288
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients.
Wu Y; Li P; Zhang H; Shi Y; Wu H; Zhang J; Qian Y; Li C; Yang J
Int J Cancer; 2013 Jan; 132(2):E37-47. PubMed ID: 22890912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
